Analyst Price Target is $25.50
▲ +34.28% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for SWK in the last 3 months. The average price target is $25.50, with a high forecast of $26.00 and a low forecast of $25.00. The average price target represents a 34.28% upside from the last price of $18.99.
Current Consensus is
The current consensus among 2 contributing investment analysts is to buy stock in SWK. This Buy consensus rating has held steady for over two years.
SWK Holdings Corp. engages in financial and asset management in the field of pharmaceuticals. The company offers capital and investments in life science companies, institutions, and inventors. It operates through the Finance Receivables and Pharmaceutical Development segments. The Finance Receivables segment is a healthcare capital provider which offers customized financing solutions to a broad range of life science companies, institutions, and investors. It is primarily focused on monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. The Pharmaceutical Development segment strategy is to utilize the Peptelligence platform to create a wholly-owned portfolio of milestone and royalty income by out-licensing the technology. The company was founded in July 1996 and is headquartered in Dallas, TX.